Axsome Therapeutics (AXSM) Expected to Post Quarterly Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($1.23) per share and revenue of $121.22 million for the quarter.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. On average, analysts expect Axsome Therapeutics to post $-3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $106.27 on Monday. The company's fifty day moving average price is $115.54 and its 200-day moving average price is $103.24. The stock has a market cap of $5.18 billion, a PE ratio of -17.74 and a beta of 0.88. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $139.13.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. William Blair restated an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Leerink Partners upped their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a research note on Monday, February 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, April 1st. Morgan Stanley boosted their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Finally, Truist Financial raised their price target on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Axsome Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $169.80.

Insiders Place Their Bets

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.40% of the stock is currently owned by insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.